Kuangli Bio-Tech Holdings Co., Ltd. (6431) AI Stock Analysis

Kuangli Bio-Tech Holdings Co., Ltd.

(TWSE:6431)

Select Model

Rating:38Underperform

Price Target:TWD 14.00▼(-3.78% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is driven primarily by severe profitability and cash-flow weakness, compounded by a bearish technical trend and limited valuation support. Positive equity and assets provide only modest offsetting support.

Positive Factors

Moderate LeverageDebt below equity indicates leverage is meaningful but not extreme, giving the company more financial flexibility than a highly indebted business. This can help preserve funding options and reduce balance-sheet strain over the next several quarters, provided losses do not continue worsening.

Negative Factors

Persistent LossesFour consecutive years of losses show that the business has not yet established a durable profit model after its profitable 2021. Continued losses reduce internally generated capital, weaken returns, and make future investment or expansion more dependent on external financing.

Kuangli Bio-Tech Holdings Co., Ltd. (6431) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.44B
Dividend Yield: ―
Average Volume (3M): 88.65K
Price to Earnings (P/E): -7.3
Beta (1Y): 0.26
Revenue Growth: -14.57%
EPS Growth: 13.16%
Country: TW
Employees: 180
Sector: General
Sector Strength: 55
Industry: Household & Personal Products

Kuangli Bio-Tech Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

Kuangli Bio-Tech Holdings Co., Ltd. operates in cosmetics and medical biotechnology. Its Shanghai operations provide OEM/ODM manufacturing of cosmetics and skin-care products, and its Taiwan operations focus on medical biotech, including longevity me...

Kuangli Bio-Tech Holdings Co., Ltd. Financial Statement Overview

Summary

Weak profitability and cash generation outweigh the company’s positive equity and asset base. Revenue declined, net loss reached 193.0 million, operating cash flow was negative 145.3 million, free cash flow was negative 154.5 million, and debt increased.

Income Statement

12Very Negative

Balance Sheet

52Neutral

Cash Flow

8Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	363.27M	377.03M	381.30M	293.37M	342.16M	358.20M
Gross Profit	76.13M	70.41M	68.32M	66.30M	68.69M	91.55M
EBITDA	-78.70M	-92.46M	-82.61M	-48.85M	-9.46M	107.52M
Net Income	-190.51M	-193.04M	-172.79M	-104.16M	-71.00M	55.95M
Balance Sheet
Total Assets	1.13B	1.19B	910.20M	1.04B	1.12B	1.25B
Cash, Cash Equivalents and Short-Term Investments	221.67M	310.17M	41.59M	90.83M	163.05M	183.03M
Total Debt	509.04M	487.33M	336.82M	421.52M	349.75M	348.33M
Total Liabilities	620.74M	607.01M	450.24M	485.34M	442.81M	506.63M
Stockholders Equity	505.41M	577.39M	459.97M	557.92M	672.74M	482.27M
Cash Flow
Free Cash Flow	-217.76M	-154.47M	-82.68M	-87.58M	-43.46M	-18.91M
Operating Cash Flow	-192.61M	-145.33M	-65.23M	-62.36M	-9.24M	21.69M
Investing Cash Flow	-31.96M	14.07M	62.25M	-30.51M	-3.16M	-93.45M
Financing Cash Flow	68.07M	314.06M	-16.07M	17.52M	-11.07M	121.01M

Kuangli Bio-Tech Holdings Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6431 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:3164	71Outperform	TWD 1.44B	23.26	―	4.78%	1.32%	80.16%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6846	55Neutral	TWD 1.33B	12.56	―	8.05%	-3.09%	-27.22%
TW:4190	43Neutral	TWD 1.29B	-13.64	―	2.28%	-1.05%	34.07%
TW:4127	40Underperform	TWD 1.65B	23.91	―	―	52.12%	―
TW:6431	38Underperform	TWD 1.45B	-7.35	―	―	-14.57%	13.16%

* General Sector Average

Performance Comparison

TW:6431 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6431	Kuangli Bio-Tech Holdings Co., Ltd.	14.55	-1.75	-10.74%
TW:3164	GenMont Biotech, Inc.	16.75	-0.96	-5.41%
TW:4127	Tien Liang Biotech Co., Ltd.	36.15	4.40	13.86%
TW:4190	Jourdeness Group Ltd.	21.95	-8.83	-28.70%
TW:6846	Greenyn Biotechnology Co., Ltd.	49.00	-24.13	-32.99%
TW:6886	Far East Bio-Tec. Co., Ltd.	36.70	-4.66	-11.27%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Kuangli Bio-Tech Holdings Co., Ltd. AI Stock Analysis